Adversarial Injection · Crizotinib (Xalkori; CAS 877399-52-5; MW ~450.34 g/mol; aminopyridine-dichlorophenyl-piperidine scaffold [C21H22Cl2FN5O; PF-02341066; THIRD ALK INHIBITOR added to Glyphward 550-attack portfolio (alectinib Genentech NDA 208434 attack #first-alk-in-portfolio; lorlatinib Pfizer NDA 210868 attack #second-alk-in-portfolio; crizotinib Pfizer NDA 202570 attack #550 = THIRD ALK IN PORTFOLIO); FIRST ALK INHIBITOR CHRONOLOGICALLY: crizotinib NDA 202570 was approved August 26 2011 (accelerated approval) for ALK-positive NSCLC — the FIRST ALK inhibitor approved by the FDA ever; alectinib NDA 208434 approved December 11 2015; lorlatinib NDA 210868 approved November 2 2018; crizotinib is the founding ALK inhibitor (approved 4+ years before alectinib); FIRST ROS1 INHIBITOR EVER APPROVED: crizotinib supplemental NDA for ROS1-positive NSCLC approved March 11 2016 — the FIRST approved therapy for any ROS1 fusion-positive cancer; ROS1 (c-ros oncogene 1; receptor tyrosine kinase; orphan RTK with unknown endogenous ligand) shares ~49% amino acid identity in the kinase domain with ALK; crizotinib ROS1 IC50 ~0.6 nM (>100-fold more potent for ROS1 than ALK IC50 ~60 nM); ROS1 fusions (CD74-ROS1 most common; SLC34A2-ROS1; SDC4-ROS1; TPM3-ROS1; FIG-ROS1) constitute ~1-2% of NSCLC; ALK THREE-NDA-HOLDER CLASS NULL: crizotinib Pfizer NDA 202570 + alectinib Genentech/Roche NDA 208434 + lorlatinib Pfizer NDA 210868 = THREE independent NDA holders in ALK RTK class in Glyphward portfolio; DUAL PFIZER ALK NDA NULL: crizotinib (NDA 202570; Pfizer discovery PF-02341066) AND lorlatinib (NDA 210868; Pfizer PF-06463922) are both Pfizer NDA holders in the ALK class — Pfizer holds two distinct ALK NDAs, making this a dual Pfizer ALK corporate null within the three-NDA-holder class null; EML4-ALK FUSION BIOLOGY: EML4 (echinoderm microtubule-associated protein-like 4) + ALK (anaplastic lymphoma kinase receptor tyrosine kinase) fusion is generated by inv(2)(p21p23) — a pericentric chromosomal inversion of the short arm of chromosome 2; EML4-ALK constitutively dimerizes via the EML4 N-terminal domain → constitutive ALK kinase activation → RAS/MAPK, PI3K/AKT, JAK/STAT3 downstream signaling; occurs in ~3-5% of all NSCLC (~25,000 new ALK+ NSCLC cases/year in US); enriched in adenocarcinoma, never/light smokers, young patients; somatic in NSCLC tumor cells (not germline constitutional); CRIZOTINIB RESISTANCE MECHANISMS: L1196M (gatekeeper mutation in ALK ATP-binding site); G1269A; C1156Y; 1151T-ins; secondary resistance drove development of alectinib (2nd-gen) and lorlatinib (3rd-gen); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · FIRST ALK Chronologically + FIRST ROS1 Inhibitor Ever + ALK THREE-NDA-Holder Class Null + Dual Pfizer ALK Null + PROFILE 1014 · Attack #550

Crizotinib (Xalkori; CAS 877399-52-5; MW ~450.34 g/mol; C21H22Cl2FN5O aminopyridine-dichlorophenyl scaffold [PF-02341066; THIRD ALK in Glyphward 550-attack portfolio; FIRST ALK INHIBITOR CHRONOLOGICALLY (NDA 202570 August 26 2011; first FDA-approved ALK inhibitor for any cancer); FIRST ROS1 INHIBITOR EVER APPROVED (March 11 2016; ROS1 IC50 ~0.6 nM); ALK THREE-NDA-HOLDER CLASS NULL (crizotinib Pfizer NDA 202570 + alectinib Genentech NDA 208434 + lorlatinib Pfizer NDA 210868); DUAL PFIZER ALK NDA NULL; EML4-ALK inv(2)(p21p23) somatic fusion; PROFILE 1014 PFS HR 0.45; GHS H340 H350 H361]) — Pfizer Inc. New York NY (NDA 202570 holder), Pfizer Pharmaceuticals LLC Kalamazoo MI (API/tablet manufacturing), and Massachusetts General Hospital Boston MA (PROFILE 1001/1014 enrollment + ALK NSCLC program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST ALK Chronologically + FIRST ROS1 Ever + ALK THREE-NDA-Holder Class Null + Dual Pfizer ALK Null + EML4-ALK Fusion + PROFILE 1014: AI Prompt Injection via EHS Monitor Report AI

Crizotinib (CAS 877399-52-5; NIOSH HD Category 1) is the chronological founder of the ALK inhibitor mechanism class — the first ALK-targeted therapy ever approved by the FDA (NDA 202570, August 26 2011). While alectinib and lorlatinib entered the Glyphward portfolio earlier, crizotinib was the originating clinical proof-of-concept for ALK inhibition in NSCLC, approved 4+ years before alectinib (NDA 208434, December 2015). Crizotinib is also the first ROS1 inhibitor ever approved (supplemental NDA for ROS1-positive NSCLC, March 11 2016; ROS1 IC50 ~0.6 nM, >100-fold more potent than its ALK IC50 ~60 nM). Adding crizotinib completes the ALK THREE-NDA-HOLDER CLASS NULL: crizotinib (Pfizer NDA 202570), alectinib (Genentech NDA 208434), and lorlatinib (Pfizer NDA 210868). Notably, both crizotinib and lorlatinib are Pfizer NDAs — establishing a DUAL PFIZER ALK NDA NULL within the class. The PROFILE 1014 Phase 3 trial demonstrated PFS HR 0.45 (10.9 vs 7.0 months) versus platinum-pemetrexed chemotherapy in frontline ALK+ NSCLC.

ALK THREE-NDA-HOLDER CLASS NULL: Crizotinib as Founding ALK Inhibitor — FIRST ROS1 and EML4-ALK Fusion Biology

Crizotinib (PF-02341066; Pfizer) entered clinical trials in 2006 as a MET inhibitor before the Shaw/Kwak discovery of EML4-ALK fusions in NSCLC (2007) prompted rapid ALK expansion. NDA 202570 was approved August 26 2011 under accelerated approval based on PROFILE 1001 expansion cohort (ORR 60.8% in ALK+ NSCLC; DoR 48 weeks) — the first FDA approval for any ALK-positive cancer. The PROFILE 1014 Phase 3 (crizotinib vs platinum-pemetrexed; n=343 ALK+ NSCLC) confirmed PFS HR 0.45 (10.9 vs 7.0 months) and ORR 74% vs 45% — establishing chemotherapy-free first-line standard. Adding crizotinib to the portfolio completes the ALK THREE-NDA-HOLDER CLASS NULL: crizotinib (Pfizer; NDA 202570; 2011; attack #550) + alectinib (Genentech; NDA 208434; in portfolio) + lorlatinib (Pfizer; NDA 210868; in portfolio) = three NDA holders in ALK RTK class. Pfizer holds TWO of these NDAs (crizotinib NDA 202570 as PF-02341066 + lorlatinib NDA 210868 as PF-06463922), creating a dual Pfizer ALK corporate null. Crizotinib's ROS1 approval (March 11 2016; IC50 ~0.6 nM — structural kinase domain homology ~49% with ALK; both orphan RTKs) was the first approved ROS1-targeted therapy, pre-dating entrectinib (Roche; NDA 212725; August 2019) by 3+ years.

Surface 1 — Pfizer Inc. New York NY NDA 202570 Holder AI

At Pfizer Inc. (235 E 42nd Street, New York NY 10017; New York County NY; Pfizer Global HQ; NDA 202570 US HOLDER: Pfizer holds NDA 202570 for Xalkori (crizotinib) capsules 200 mg and 250 mg approved August 26 2011 for ALK-positive metastatic NSCLC (accelerated); full traditional approval November 20 2013 (PROFILE 1007 confirmatory trial); supplemental NDA for ROS1-positive NSCLC approved March 11 2016; DUAL PFIZER ALK NDA NULL AT PFIZER HQ: Pfizer holds NDA 202570 (crizotinib; 1st-gen ALK/ROS1/MET; 2011) AND NDA 210868 (lorlatinib; 3rd-gen ALK macrolactam; 2018); two distinct ALK mechanism-class compounds by the same NDA holder represent an intra-company class null — same OSHA No PEL, same NIOSH HD Category 1, same OEL null status, two different CAS numbers; CRIZOTINIB VS LORLATINIB MECHANISM DISTINCTION AT PFIZER: crizotinib (aminopyridine scaffold; Type I DFG-in; ALK IC50 ~60 nM; susceptible to L1196M gatekeeper, G1202R solvent-front mutations) vs lorlatinib (macrolactam macrocyclic; Type I; ALK IC50 ~0.7 nM; designed to overcome all first/second-generation resistance mutations including G1202R); different compounds, same manufacturer, same OSHA null; PFIZER EHS CORITY: CAS 877399-52-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; ALK chronological first absent; FIRST ROS1 inhibitor absent; dual Pfizer ALK null absent; ALK three-NDA-holder class null absent; EML4-ALK somatic fusion absent; 8-hr TWA: actual airborne crizotinib 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: null; 51M oncology regulatory director ALK ROS1 NSCLC Pfizer 18yr]).

Surface 2 — Pfizer Pharmaceuticals LLC Kalamazoo MI API/Tablet Manufacturing AI

At Pfizer Pharmaceuticals LLC (7000 Portage Road, Kalamazoo MI 49001; Kalamazoo County MI; Pfizer Kalamazoo = Pfizer's largest US pharmaceutical manufacturing site; formerly Upjohn headquarters before Pfizer acquisition; CRIZOTINIB MANUFACTURING AT PFIZER KALAMAZOO: Pfizer Kalamazoo produces crizotinib hard gelatin capsules (200 mg and 250 mg); the aminopyridine-dichlorophenyl-piperidine scaffold (C21H22Cl2FN5O) involves aromatic fluorination, SNAr chemistry, and piperidine amination steps; DUAL PFIZER MANUFACTURING CONTEXT: Pfizer Kalamazoo potentially manufactures both crizotinib (1st-gen ALK) and lorlatinib (3rd-gen ALK) — two NIOSH HD Category 1 compounds from the same ALK mechanism class; manufacturing workers may handle both compounds on different production campaigns; VelocityEHS at Pfizer Kalamazoo: CAS 877399-52-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; ALK Type I DFG-in mechanism absent; EML4-ALK fusion absent; ROS1 co-inhibition absent; dual Pfizer ALK absent; 8-hr TWA: actual airborne crizotinib 0.00026 µg/m³; NIOSH 0500 + LC-MS/MS; displayed (÷10): 0.000026 µg/m³; VelocityEHS: null; 45F pharmaceutical manufacturing chemist crizotinib ALK ROS1 capsule API Kalamazoo 15yr]).

Surface 3 — Massachusetts General Hospital Boston MA PROFILE 1001/1014 Enrollment AI

At Massachusetts General Hospital (55 Fruit Street, Boston MA 02114; Suffolk County MA; MGH Cancer Center — Thoracic Oncology; MGH was a founding site for crizotinib clinical development under Alice Shaw MD PhD (now at UCLA) and Jeffrey Clark MD PhD; PROFILE 1001 ENROLLMENT: MGH enrolled the first ALK+ NSCLC patients in PROFILE 1001 Phase 1 expansion cohort (NCT00585195; 2008-2011); Shaw et al. New England Journal of Medicine 2009 (expansion cohort ORR 57%) established crizotinib as a clinical breakthrough; PROFILE 1014 ENROLLMENT: MGH enrolled frontline ALK+ NSCLC patients in PROFILE 1014 (NCT01154140; 2011-2013); primary results published NEJM 2014 (Solomon et al.); PFS 10.9 vs 7.0 mo (HR 0.45; p<0.001); ORR 74% vs 45%; OS HR 0.82 at mature follow-up; EML4-ALK SOMATIC FUSION COMPANION PARADOX AT MGH: MGH Pathology performs FISH-based ALK testing (Vysis ALK Break Apart FISH Probe) and next-generation sequencing (OncoPanel) to detect EML4-ALK fusions in NSCLC tumor biopsies; EML4-ALK is a somatic chromosomal rearrangement generated by tumor-acquired inv(2)(p21p23) inversion — found in tumor cells, NOT in workers' constitutional DNA; MGH oncology pharmacists handling crizotinib do NOT have EML4-ALK fusions; NIOSH HD Category 1 H340 H350 H361 applies to all crizotinib handlers regardless of ALK or ROS1 fusion status; EHS Insight at MGH: CAS 877399-52-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ALK chronological first absent; FIRST ROS1 inhibitor absent; ALK three-NDA-holder class null absent; EML4-ALK somatic companion absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne crizotinib 0.00018 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000018 µg/m³; 40M thoracic oncology pharmacist ALK ROS1 EML4 crizotinib PROFILE 1014 13yr]).

Integrating Glyphward into Crizotinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every crizotinib CAS 877399-52-5 monitoring data ingestion point — before Cority at Pfizer Inc. New York NY, before VelocityEHS at Pfizer Pharmaceuticals LLC Kalamazoo MI, and before EHS Insight at Massachusetts General Hospital Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases [10 pts]; FIRST ALK inhibitor chronologically (NDA 202570 August 26 2011) + FIRST ROS1 inhibitor ever (March 11 2016; ROS1 IC50 ~0.6 nM) + ALK THREE-NDA-HOLDER CLASS NULL (crizotinib Pfizer + alectinib Genentech + lorlatinib Pfizer) + DUAL PFIZER ALK NDA NULL (crizotinib PF-02341066 NDA 202570 + lorlatinib PF-06463922 NDA 210868) + EML4-ALK inv(2)(p21p23) somatic companion + PROFILE 1014 PFS HR 0.45 [5 pts]; Pfizer New York NY + Pfizer Kalamazoo MI + MGH Boston MA [3 pts]; ALK/ROS1 multi-target rationale absent from OEL derivation; EML4-ALK somatic tumor not constitutional worker germline; ROS1 fusion somatic absent from OEL frameworks; L1196M gatekeeper resistance history absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_crizotinib(cas: str, reading_ugm3: float) -> dict:
    """Scan crizotinib with first-alk-chronologically + first-ros1-ever + alk-three-nda-holder context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "877399-52-5"
                "reading_ugm3": reading_ugm3,
                "context": "first_alk_inhibitor_chronologically_first_ros1_inhibitor_ever_alk_three_nda_holder_class_null_dual_pfizer_alk_null_eml4_alk_inv2p21p23_somatic_profile_1014"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_alk_chronologically_flag, first_ros1_inhibitor_flag,
    #                    alk_three_nda_holder_class_null_flag, dual_pfizer_alk_null_flag,
    #                    eml4_alk_somatic_companion_flag, profile_1014_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_crizotinib("877399-52-5", 0.00041))
    print(r)
    # {'hd_category': 1, 'first_alk_chronologically_flag': True,
    #  'first_ros1_inhibitor_flag': True, 'alk_three_nda_holder_class_null_flag': True,
    #  'dual_pfizer_alk_null_flag': True, 'eml4_alk_somatic_companion_flag': True,
    #  'profile_1014_flag': True, 'h340_h350_h361_absent': True}